TYRA Earnings & Financial Statements
Tyra Biosciences, Inc.
$19.97
-$0.43(-2.08%)
33
Overall
60
Value
10
Tech
31
Quality
Market Cap
$1.40B
Volume
194.68K
52W Range
$12.98 - $40.65
Target Price
$47.45
TYRA earnings and financial statements: Tyra Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TYRA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M |
| EBITDA | -$119.40M | -$85.96M | -$68.84M | -$58.63M | -$26.15M |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M |
| EPS (diluted) | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-1.91 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $282.61M | $363.56M | $225.86M | $266.18M | $306.70M |
| Total liabilities | $23.43M | $20.41M | $21.59M | $8.35M | $4.96M |
| Shareholders’ equity | $259.18M | $343.15M | $204.26M | $257.83M | $301.74M |
| Cash and equivalents | $77.39M | $91.97M | $58.01M | $251.21M | $302.18M |
| Long-term debt | $5.34M | $5.81M | $6.22M | $2.48M | $981.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M |
| Capital expenditure | -$141.0K | -$664.0K | -$770.0K | -$559.0K | -$661.0K |
| Free cash flow | -$95.28M | -$70.44M | -$50.91M | -$50.84M | -$24.41M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TYRA | $19.97 | -2.1% | 194.68K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |